The hypertrophic heart rat (HHR) was derived from the spontaneously hypertensive rat of the Okamoto 
Introduction
Left ventricular hypertrophy (LVH) is a major independent risk factor predictive of cardiovascular mortality and morbidity. In the Framingham study, over 50% of individuals with electrocardiographic evidence of LVH were dead within 8 years as a result of significantly increased rates of cardiac failure, sudden cardiac death and arrhythmia ( 1 ) . Interestingly, not all subjects with hypertension develop LVH and in other instances the increase in LV mass for a given hemodynamic load is inappropriately high ( 2 -4 ) . Similarly, in a classic survey of rat strains, Tanase et al . showed that although high blood pressure (> 150 mmHg) was associated with large hearts, there was marked variation in heart size among normotensive animals ( 5 ) . In order to provide a model of spontaneous, normotensive cardiac hypertrophy, we derived the hypertrophic heart rat (HHR) strain by the selective inbreeding of offspring that had both large hearts and normal blood pressures. These offspring had been derived, in turn, from a cross between spontaneously hypertensive rats (SHR) of the Okamoto strain and normotensive Fisher 344 animals. As expected, the inbred HHR strain derived through this process exhibits spontaneous cardiac hypertrophy in the absence of hypertension ( 6 ) . While the inherent determinants of the pressure-independent cardiac hypertrophy of HHR have not been identified, they are presumably largely genetic.
A considerable amount is known about the molecular physiology of cardiac hypertrophy, including the identity of a number of genetic pathways that might mediate cardiac enlargement in the HHR. For example, the activation of proto-oncogenes ( e.g. , Egr-1 , c-fos , c-jun , c-myc ) that encode for peptide transcription factors is believed to induce the transcription of other hypertrophy-related genes ( 7) . This socalled "early response" by the proto-oncogenes induces a "fetal gene program" characterized by the re-expression of several genes normally expressed predominantly in the embryonic heart. These genes include those encoding atrial natriuretic factor (ANF) and fetal isoforms of contractile proteins such as β-myosin heavy chain, α-skeletal actin and α-smooth muscle actin (7) . Concurrent with this re-expression of fetal genes is the down-regulation of genes normally expressed at higher levels in the adult heart, such as α-myosin heavy chain and the sarcoplasmic reticulum calcium pump, SERCA2a (7) . These changes in gene expression are believed to be indicative of cardiomyocyte hypertrophy and its associated increase in the production and assembly of contractile proteins into sarcomeric units (8) .
Of the 15,000 or more genes estimated to comprise the mammalian genome, it has been shown that over two-thirds are expressed in cardiovascular tissues (9) . Therefore, a caseby-case examination of candidate genes playing a role in the cardiac hypertrophy of the HHR is currently impracticable. High-throughput DNA microarray technology offers a more effective means of uncovering genetic pathways involved in cardiac growth. DNA microarrays consist of large numbers of cDNA or oligonucleotide probes spotted onto a glass slide using a precise robotic system (10) . Such arrays are used to simultaneously identify genes that are differentially expressed between different cell states or tissue types. At present, DNA microarray studies investigating gene expression in cardiac hypertrophy have suggested that hypertrophyregulated genes are largely specific to the hypertrophy-inducing stimulus (11) and furthermore can be grouped into clusters or "regulons" representing families of genes involved in distinct pathways mediating cardiomyocyte growth (12) . Genes specifically altered during the development of hypertrophy include those encoding secreted growth factors, receptors, intracellular signaling molecules, proteins involved in intermediary metabolism, structural proteins, transcription factors and protein synthetic genes (12) . However, determining which expression changes are causative and which are secondary cellular responses is a considerable challenge.
In the present study, we have used cDNA microarrays to compare the gene expression profiles in left ventricular cardiac tissue from the HHR and its genetic control strain, the normal heart rat (NHR). Gene expression of HHR and NHR was compared at 8-10 weeks of age (i.e., in young rats), which was chosen to represent the stage of cardiac hypertrophy in the HHR that coincided with the period of body and heart growth (6). Gene expression was also compared between strains at 38-50 weeks (i.e., in old rats), when the growth rate of the animal has largely plateaued. In this way we hoped to determine which genes play a developmental, as opposed to a maintenance role in the cardiac hypertrophy of the HHR. Given that the HHR is normotensive, we also sought to identify primary (causal) hypertrophy genes, rather than those that are induced secondarily to an elevated blood pressure. In doing so we also hoped to identify those SHR genes captured in the HHR and which contribute to the component of the SHR's cardiac hypertrophy that is blood pressure-independent.
Methods

Animals
Male HHR and NHR animals were obtained from the Biological Research Facility (University of Melbourne, Victoria, Australia). Animals were housed under standard conditions with a 12-h light/dark cycle and room temperature maintained at 18-21°C. Animals received standard laboratory fodder (Clarke King, Pakenham, Australia) and tap water ad libitum. All experiments received prior approval by the Animal Experimentation Ethics Committee of the University of Melbourne. Investigations complied with both the Code of Conduct for the Care and Use of Animals as specified by the National Health and Medical Research Council of Australia, as well as the "Guide for the Care and Use of Laboratory Animals" published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Blood Pressure Measurements and Tissue Processing
Approximately 1 week before euthanasia, systolic blood pressure measurements were recorded for all HHR and NHR using tail-cuff plethysmography (13) . Systolic blood pressure was recorded 5 times on two consecutive days, the first day being used solely to adapt the animals to the tail-cuff procedure. On the second day the first of the 5 measures was discarded and the average of the subsequent 4 measures was used as the representative blood pressure for each animal. Because the blood pressure values were not normally distrib-uted, they were expressed as the median and interquartile ranges, and comparisons were made between groups using the non-parametric Kolmogorov-Smirnov test. The body mass of male HHR and NHR was recorded at 8-10 weeks of age or at 38-50 weeks of age. After induction of surgical anaesthesia with sodium pentobarbitone (60 mg/kg, i.p., Nembutal; Boehringer Manheim, North Ryde, Australia), hearts were excised and then rinsed in phosphate-buffered saline (Sigma, St. Louis, USA). Non-cardiac tissue was trimmed away from the heart, following which it was blotted dry and weighed. The left ventricle was then dissected and immediately frozen in liquid nitrogen. All tissues were stored at −70°C until later use. Total RNA was extracted using Trizol Reagent (GibcoBRL LifeTechnologies, Gaithersburg, USA) according to the manufacturer's recommended protocol. The RNA was then resuspended in 50 μL ultra pure H2O and stored at −70°C.
DNA Microarrays
The microarray slides were produced at the Australian Genome Research Facility in Melbourne via robotic printing (ChipWriter; Virtek, Waterloo, Canada). PCR-amplified cDNA clones were arrayed at high density onto Corning CMT-GAPS aminosilane-coated glass slides (Corning, New York, USA). The specific clone set printed onto the slides was the NIA 15K mouse cDNA clone set (National Institute of Aging [NIA] , National Institute of Health [NIH]; http:// lgsun.grc.nia.nih.gov/). This clone set was derived from 11 embryo cDNA libraries and one newborn ovary cDNA library and represents 15,247 (15K) unique genes of which approximately 50% are novel (expressed sequence tags [ESTs]; segments of genes that have been sequenced but have no known function) and the remainder are known genes (14) . The arrays included a selection of control spots including housekeeping genes and positive, negative and calibration controls. Each probe was printed on slides in duplicate and side-by-side in rows resulting in a total of 32,448 spots in a 12 × 4 grid layout. The microarrays slides were stored in a desiccated, dustand light-free environment
Labeling of cDNA Probes
The CyScribe cDNA Post Labeling Kit (Amersham Pharmacia, Buckinghamshire, UK) was used to prepare the Cy3-and Cy5-labeled cDNA used in the microarray hybridizations. Five 8-10 week-old HHR rats were age-matched with five NHR animals and a dye-swap pair of microarrays was hybridized with labeled cDNA from each matched pair. Four 38-50 week-old HHR were age-matched with four NHR rats and again a dye-swap pair of microarrays was hybridized from each pair. This produced 10 microarrays comparing young NHR with young HHR and eight arrays comparing old NHR with old HHR. A total of 100 μg total RNA per dye labeling reaction was used for each HHR vs. NHR comparison, giving a total of 200 μg total RNA per array (2 labeling reactions per array). Microcon filters (Microcon) were utilized for the purification of the cDNA, and QIAquick columns (Qiagen, Hilden, Germany) were used for the purification of CyDyelabeled cDNA, both in accordance with the manufacturer's recommended protocol. All reactions following CyDye-labeling were carried out in 1.5 mL amber eppendorf tubes to minimize the effect of UV-light on the CyDyes.
Microarray Hybridization
Prior to hybridization, the cDNA microarrays were incubated in a pre-hybridization buffer (10 mg/mL BSA-fraction
) in a clean slide mailer for 1 h at 42°C. Following incubation, the slides were washed under distilled water and, after drying with a compressed air gun, immediately used for hybridizations. The following blocking agents were added to the purified CyDye-labeled cDNA: 25 μL 1 mg/μL Mouse Cot 1DNA (Gibco BRL), 3.8 μL 10 mg/mL Poly A (Amersham Pharmacia), and 5.0 μL 10 mg/mL Salmon Sperm DNA (Gibco BRL). The hybridization reaction was spun down in a rotary evaporator until a volume of 30 μL was achieved. Thirty microliters 2 × hybridization buffer (50% formamide (Sigma), 10 × SSC (Sigma), and 0.2% SDS) was added to the 30 μL hybridization reaction, heated at 100°C for 2 min and pipetted using capillary action underneath a 60 × 25 mm cover-slip (Grale Scientific, Ringwood, Australia) placed over the array region on the pre-hybridized microarray slide. The microarray slide was then placed in a hybridization chamber (Corning) and incubated for 16-20 h in a pre-heated water bath at 42°C. Prior to scanning, the microarray slide was gently washed with 1 × SCC (Sigma), 0.2% SDS (Sigma) buffer solution for 5 min, 0.1 × SSC, 0.2% SDS buffer solution for 5 min, and twice with 0.1 × SSC buffer solution for 2 min at room temperature. The microarray slide was spun dry in a plate centrifuge at 500 × g for 12 min.
Data Analysis
The hybridized slides were scanned using a GenePix 4000B Scanner (Molecular Devices, Sunnyvale, USA) to produce single-image 16-bit TIFF files. Intensity information was extracted for each spot using the image analysis package Spot (15) . Background correction used the "morph" morphological background measure (16) . The data was normalized using print-tip loess normalization (17) . Log-fold changes were estimated by fitting a gene-wise linear model to the log-ratios from all 18 arrays with coefficients (18) . The coefficients from the model measured the log-ratio of expression in the direct comparisons of "young" HHR vs. NHR animals and "old" HHR vs. NHR animals, and their contrast provided an indirect comparison of old vs. young animals. Since each probe was printed in duplicate on each array, the linear models were fitted using the generalized least squares method HHR, hypertrophic heart rat; NHR, normal heart rat; ESTs, expressed sequence tags. *Multiple accession numbers referring to the same gene are summarised as one entry. Full results are available for download at http://www.physiology.unimelb.edu.au/ † Unknown genes/ ESTs are listed separately and available for download at http://www.physiology.unimelb.edu.au/ with an estimated value for the correlation between duplicate spots. The correlation estimate was 0.88. This had the effect of increasing the degrees of freedom available to estimate the gene-wise variances compared with simply averaging the duplicate log-ratios (19) .
Differential expression was assessed using a parametric empirical Bayes model which moderates the standard errors for the test statistics by borrowing information across genes (18) . This results in far more stable inference when the number of microarrays in the experiment is not large. Genes were considered to be differentially expressed if their posterior logodds (B-statistic) were positive, i.e., if the estimated odds of being differentially expressed was greater than 50-50. All analysis was carried out using the "Limma" software module (20) .
Annotated genes were classified by their function (21) with reference to the Gene Ontology database (http:// www.geneontology.org/) (22) . The SOURCE genomic database (http://source.stanford.edu/) (23) was used to determine whether the annotated genes had been previously shown to be expressed in the mouse heart.
Microarray Verification by Quantitative Real-Time PCR
Real-time PCR (RT-PCR) was used to corroborate the folddifferences in RNA levels detected by the microarrays as existing between species. Total RNA from "old" HHR and NHR tissues was extracted using Trizol reagent (Invitrogen Life Technologies, Melbourne, Australia) according to the manufacturer's recommended protocol. Reverse transcription using 5 μg of RNA was performed using the ReactionReady First Strand cDNA Synthesis Kit (SuperArray Bioscience, Frederick, USA). RT 2 Real-Time Gene Expression Assay Kits (SuperArray Bioscience) were used according to the manufacturer's instructions. Four genes were targeted in this approach: natriuretic peptide precursor type B (Nppb; rat NM_031545), mitogen activated protein kinase 1 (Mapk1; rat NM_053842), tropomyosin 1 (Tpm1; rat NM_019131) and TRAF family member-associated NF-κB activator (Tank; rat NM_145788). The "housekeeper gene" ribosomal protein L13a (Rpl13a; rat NM_173340) was used as a control and showed no significant differential expression in our microarray results (fold change= 0.94, B= −4.9). SYBR green I (Molecular Probes, Eugene, USA) was included in the RT-PCR reactions, which contained the following: 1 μL cDNA, 2.5 μL 5 × SYBR Green I solution, 1 μL gene specific primer mix, 12.5 μL 2 × PCR cocktail and ultra-pure H2O to a final volume of 25 μL. PCR reactions were carried out on a Rotor Gene 3000 thermal cycler (Corbett Research, Sydney, Australia). Cycling conditions included an initial incubation at 95°C for 10 min followed by 40 cycles of denaturing at 95°C for 30 s, annealing at 55°C for 30 s, and elongation at 72°C for 30 s. At the end of the PCR cycle, a dissociation curve was generated to ensure the amplification of a single product. A cycle threshold (CT) was calculated for each gene and defined as the number of PCR cycles required for a PCR reaction to reach a fluorescence value within the linear amplification range. The relative fold-difference between strains for a given target gene was calculated using the so-called 2 −ΔCT method (24) . CT values for each gene were normalized against the value for the "housekeeper gene" (Rpl13a) prior to calculation of fold-differences between strains. Each reported fold change for a gene represents the average of two independent RT-PCR runs, which were each performed in triplicate.
Results
Blood Pressure and Cardiac Measurements
There were no significant differences in systolic blood pressure between the HHR and NHR at either the young or old ages (Table 1 ). There was also no significant difference in body weight between the HHR and NHR groups at either 8-10 weeks or 38-50 weeks, although the NHR showed a tendency to increase in body weight. As expected, a significant increase in heart weight and the heart weight-to-body weight ratio was seen in the HHR group compared with the NHR group (p< 0.05) at both 8-10 weeks and 38-50 weeks of age. In both the HHR and NHR, the heart weight-to-body weight ratio was decreased in older animals, as expected.
Fig 1. Functional classification of clones differentially expressed in both young (8-10 weeks) and old (38-50 weeks) HHR. Data are expressed as a percentage of the total differentially expressed clones either over-or under-expressed relative to age-matched NHR.
(n = 65 clones) (n = 188 clones) 
Differentially Expressed Genes in Young HHR
A number of genes were found to be differentially expressed only between HHR and NHR at 8-10 weeks of age (Table 2) . With reference to the available literature, genes were grouped into eight broad functional classifications; energy/metabolism, signal transduction, matrix/structural proteins, transcription/chromatin, protein synthesis/translational control, cell defense/growth-related proteins, apoptosis and unknown. Genes are ranked in the tables by the B-statistic with over-expressed genes (positive log-ratio) followed by under-expressed genes (negative log change). The log ratios are base 2, and thus a log ratio equal to one corresponds to a two-fold change.
In young HHR, 65 of the 15,247 arrayed clones (0.43%) showed statistically significant differential expression (21 clones over-expressed, 44 clones under-expressed). Twentynine of these 65 clones were found to be the same as those differentially expressed in old HHR (see below). A functional annotation was ascribable to 37 (59%) of the differentially expressed clones in young HHR (Fig. 1) .
Differentially Expressed Genes in Old HHR
Genes differentially expressed in 38-50 week-old HHR and NHR, but not in young animals (8-10 weeks old), are listed in Table 3 . Relative to NHR, older HHR showed a greater proportion of differential expression than at the younger age, such that 390 clones (2.6%) showed statistically significant differential expression (98 clones over-expressed, 292 clones under-expressed). A physiological function was ascribable to 188 (49%) of these clones in old HHR (Fig. 1) .
Differentially Expressed Genes Common to Both Young and Old HHR
Of the 426 differentially expressed clones in the young and old HHR there were 29 clones (7%) that were common to both (Table 4) . A function was ascribable for 17 (59%) of these clones. The number of differentially expressed clones common to both the young and old animals is shown in Fig. 2 . 
Differentially Expressed Unknown Genes/ESTs in HHR
Many clones encoding hypothetical proteins or ESTs with no homology to known proteins exhibited notable over-expression or under-expression in the HHR. These clones are listed in the supplemental materials and are available for download at http://www.physiology.unimelb.edu.au/ftp/Supplementary DataforMicroarrayManuscript.pdf
RT-PCR Results
The results of the RT-PCR reactions and their concordance with those obtained by microarray are shown in Table 5 . Changes in gene expression are shown as mean fold changes ( Table 5 ). The PCR results for the four genes confirm the microarray results (correlation= 0.95, p< 0.05).
Discussion
In the present study, we applied cDNA microarray expression profiling to the study of pressure-independent cardiac hypertrophy with the aim of identifying differentially expressed genes in the HHR that might be associated with its cardiac hypertrophy. To this end, the relative expression of 15,427 cDNA sequences was compared in left ventricular cardiac tissue from both young HHR and NHR at 8-10 weeks, and old HHR and NHR at 38-50 weeks. In young HHR, 65 of the arrayed clones showed differential expression compared with 390 differentially expressed clones in old HHR. The fact that there were a greater number of differentially expressed genes in old HHR may represent an increase in genetic "noise" due to the cumulative effect of time and environment on the gene expression. Alternatively, it is possible that the greater differential gene expression observed in old HHR was the result of pathological changes arising from the cardiac hypertrophy in this model.
A number of genes were found to be expressed only in young or old animals, while some were differentially expressed at both ages. It is difficult to judge which set of genes warrants further investigation. While one could argue that genes differentially expressed only at a young age might be causative of cardiac hypertrophy in the HHR, it is also possible that causal genes are over-or under-expressed throughout life. If this were the case, other factors might be acting to limit cardiac growth at older ages. It might be argued, however, that genes differentially expressed only at the older age are less likely to have been involved in the development of cardiac hypertrophy. Alternatively, a causal gene might not be differentially expressed at all and could exert its action via an alteration of protein function rather than transcript level. This latter possibility remains an inherent limitation of the microarray approach.
Genes showing differential expression only in young HHR (Table 2) are involved in several cellular processes. The DnaJ (Hsp40) homolog (Dnaja3) was shown to be over-expressed (25) . Dnaja3 (alias Tid-1) has been shown to define a novel Ras GTPase-activating protein (RasGAP) binding protein (26) . Recent evidence suggests a central role for Ras, a small G-protein, in transmitting hypertrophic signals from G-protein coupled receptors, growth factor receptors and cytokine receptors to the nucleus via the Ras/mitogen activated protein kinase (MAPK) pathway and other cytosolic effectors (25) . The over-expression in old HHR of the guanine nucleotide binding protein gene (Gng5), Rab12 (a member of the Ras oncogene family) and mitogen activated protein kinase 1 (Mapk1) further suggests a role for the Ras/ MAPK signaling pathway in the etiology of cardiac enlargement in the HHR. Evidence that MAPK1 (27) (28) (29) , MAPK14 (30, 31) and MAP2K4 (32) are involved in normal and abnormal tissue growth further strengthens the possibility that these are key enzymes in the cardiotrophic process in the HHR. However, the cause and effect relationship between the activity of these enzymes and the elevated cardiac size of the HHR remains to be determined. It was of interest that transforming growth factor-β (TGF-β) was under-expressed in young HHR. A recent study has shown that human B-type natriuretic peptide (BNP) inhibits TGF-β-induced effects on primary human cardiac fibroblasts, including down-regulating TGF-β-regulated genes related to fibrosis, myofibroblast conversion, proliferation, and inflammation (33) . The mouse homologue to the polypeptide hormone BNP, natriuretic peptide precursor type B (Nppb), was over-expressed in both young and old HHR, and several matrix/structural protein-related genes (β-actin, Actb; procollagen-5, Col5a1; cartilage associated protein, Crtap) were under-expressed in young HHR. Therefore, one possibility is that the over-expression of the cardiac growth factor Nppb in the cardiac tissue of the HHR inhibits TGF-β expression and the expression of several fibrosis-related genes. Supporting this proposal is the fact that the HHR exhibits increased cardiomyocyte mass with no difference in the proportion of fibrous tissue (6) . Further studies are required to determine the role of Nppb and its gene in the HHR. The hypothesized molecular pathways by which the genes and proteins mentioned above give rise to the cardiac hypertrophy of the HHR are summarized in Fig. 3 .
Among the genes differentially expressed in old HHR, several were assigned an energy/metabolism functional annotation. Of particular interest were the 16 under-expressed mitochondrial DNA clones. Mitochondria are abundant in energy-demanding cardiac tissue, and mitochondrial biogenesis is increased during cardiac hypertrophy (34) . However, increased levels of point mutations in cardiac mitochondrial DNA and reduced levels of mitochondrial enzymatic activities may occur with aging due to increased production of reactive oxygen species (35) . Furthermore, a reduction in cardiac mitochondrial DNA levels and respiratory enzymes has been reported in patients with isolated hypertrophic cardiomyopathy and is associated with clinical cardiac dysfunction (34) . The gene encoding the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (Gapd), which was shown to be under-expressed in the old HHR in the present study, has also been shown to be impaired during cardiac oxidative stress (36) . Thus, the under-expression of mitochondrial DNA and respiratory enzymes in the HHR may reflect an altered oxidative state and cardiac dysfunction in old animals. Perhaps an adaptive response by old HHR to this state of oxidative stress might be the over-expression of the gene encod- Metallothionein-overexpressing transgenic mouse models have produced evidence of an antioxidant and protective function of metallothionein from oxidative injury in the heart (37) .
The tumor necrosis factor (TNF) receptor-associated factor (TRAF) family of proteins is involved in transducing signals from members of the TNF receptor family (38) . Genes encoding for the TRAF family member-associated nuclear factor-κB (NF-κB) activator (TANK/I-TRAF) and TRAF and TNF receptor associated protein (TTRAP) were under-expressed in old HHR. Studies have shown that over-expression of both TANK/I-TRAF and TTRAP inhibits TRAF-mediated activation of the nuclear transcription factor NF-κB (38, 39) . This is of interest because activation of NF-κB has been shown to be required for hypertrophic growth of rat neonatal ventricular cardiomyocytes (40) . Furthermore, oncogenic Ras enhances NF-κB transcriptional activity through mitogen-activated protein kinase signaling pathways (41) and angiotensin II. Angiotensin II is a potent stimulus to hypertrophy of isolated cardiomyocytes in the absence of hemodynamic load (42) , and induces gene transcription through cell-type-dependent effects on NF-κB (43) . It has also been shown that metallothionein, over-expressed in old HHR, activates NF-κB, which suggests a potential role for NF-κB in mediating the protective effects of metallothionein (44) . Thus, it is possible that the under-expression of inhibitors and over-expression of activators for NF-κB may be accentuating its activity, which in turn might contribute to the cardiac hypertrophy in the HHR.
One of the genes showing the greatest under-expression in old HHR was that encoding for α-tropomyosin (Tpm1), a component of the cardiac sarcomere. Mutations in the gene encoding α-tropomyosin (Tpm1) have been described in hypertrophic cardiomyopathy (HCM) (45) . Moreover, it has been suggested that mutations in sarcomeric proteins may have some effect on proto-oncogenes, and indeed, the expression of nuclear proto-oncogenes Ras and c-myc has been shown to be up-regulated in HCM patients (46) . It was also of interest that the gene for the cell growth inhibitor Max dimerization protein 5 (Mad5) was under-expressed in old HHR. Transcription repression is mediated by Max heterodimer formation with members of the Mad family such that overexpression of Max dimerization protein 5 can inhibit cell growth and cellular transformation by Myc and Ras (47) . Thus, it stands to reason that under-expression of Mad5 may increase the positive effects of Myc and Ras on cellular growth and gene expression in cardiac tissue of the HHR.
Genes differentially expressed at both the developmental and established hypertrophic stages in the HHR were expected to represent the common genetic events in pressureindependent cardiac hypertrophy. As mentioned previously, Nppb was over-expressed in both young and old HHR. Expression of its gene (Nppb), predominantly from the cardiac ventricles (48) , increases dramatically in response to hypertrophic stimuli (49) . The gene encoding the chloride channel subunit Clcn3 was under-expressed at both young and old ages in the HHR. An increased chloride current develops in hypertrophied rat ventricular myocytes (50) , and changes in Clcn3 mRNA levels have been shown in cardiac hypertrophy induced by abdominal aortic banding (51) . Perhaps the reduced expression of Clcn3 in the HHR is an adaptive response to a hypertrophy-induced increase in chloride current.
The genes in the HHR contributing to their cardiac hypertrophy are either hypertrophic genes transmitted from the SHR progenitors or "hypotrophic" genes not received from the F344 strain. As such, it should be possible to identify those genes differentially expressed in our study and which have also previously been reported to have an altered expression in the SHR. We would argue that such genes would be more likely to be those that cause altered heart size in the SHR and act independently of the elevated blood pressure in this strain. For example, we found differential expression of the NF-κB gene in HHR in our study, a finding which has previously been reported in SHR (52) . The suggestion by Gupta et al. that this particular gene causes cardiac hypertrophy independently of blood pressure is thus supported by our finding that the normotensive HHR has altered expression of this gene (52) . Other genes that we report as differentially expressed between HHR and NHR, and which have also been reported as having altered expression in the SHR include TGF-β1 (53, 54) , Nppb (brain natriuretic peptide) (55) (56) (57) and Mapk1 (58) . In contrast, given that we found altered expression of the chloride channel subunit gene Clcn3 in HHR, our results do not agree with the suggestion that chloride channels do not play a role in cardiac hypertrophy (59) . These genes differentially expressed in both HHR and SHR, we believe, are particularly worthy of further investigation in either strain.
Our study describes for the first time the gene expression changes in hypertrophic cardiac tissue from the HHR. Moreover, this study investigated age-specific expression changes representative of pressure-independent cardiac hypertrophy in younger and older animals. Despite the analytical power of gene expression profiling through the use of DNA microarrays, there are some limitations to studies such as those reported here. First, in the present study we hybridized rat total RNA to a mouse cDNA clone set. This may explain the low fold changes reported, especially in the HHR vs. NHR comparison at 8-10 weeks of age. However, an independent assessment of rat-mouse sequence homology in the NIA 15K clone library has suggested that inter-species use of this clone library is valid (60) . Future gene expression studies of this model will incorporate rat microarray analyses when these are more readily available. The relatively low fold changes reported may also be due to the genetic similarity of the HHR and the NHR, which were inbred from the same parental strains, the spontaneously hypertensive and Fischer 344 rats (6) . It is unlikely that large differences in gene expression will be found between similar tissues, as previous studies of gene expression in cardiac growth have reported fold-change values of 1.5-fold as significant (61) . However, we are confident that most of the putative differentially expressed genes represent real differences in gene expression given the biological and technical replication involved in the experiment and the statistical analysis of significance, which analyzed variability as well as observed fold changes. The co-identification of known hypertrophic genes adds further confidence to our results. Our data suggest candidate genetic factors that contribute to the establishment and maintenance of the cardiac hypertrophy of the HHR. Further exploration and verification of the precise role of identified genes in this process is merited.
